Search
Nektar Therapeutics
NKTRAdd to Watchlist
69.760USD
-0.890-1.26%
Close 09-11 16:00（ET）
2.38BMarket Cap
LossP/E TTM
After-hours 16:17 (ET)69.500USD-0.245-0.35%
After-hours 16:17 (ET)TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D
Today
-1.26%
5 Days
-5.97%
1 Month
-8.25%
6 Months
-0.85%
Year to Date
+65.00%
1 Year
+43.30%
Key Figures
71.410Open
71.410High
41.19KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.12%Turnover Ratio
70.650Prev. Close
68.350Low
2.86MTurnover
LossP/E Static
2.64P/B
0.00%Div Yield TTM
-31.01%ROA
109.00052wk High
19.81Volume Ratio
-118.96MNet Profit
34.13MShares
-7.9223EPS TTM
1.17Beta
-53.60%ROE
33.40052wk Low
3.58%Amplitude
100.00%Gross Margin
2.38BMarket Cap
3.23Reward/Risk
5.27%Risk Rate
Nektar Therapeutics's Score
-0.03vs previous score
Forecast8.73
Financial Health6.09
Technical3.07
Valuation Dimensions8.56
Institutional Confidence5.00
Risk Assessment5.75
Media Coverage
Coverage Level
Very Low
Very High
Neutral
Analyst Rating
Nektar Therapeutics Technical Analysis
Technical Indicators
Strong sell
Summary
Sell
Moving Average
Strong sell
Nektar Therapeutics Latest Earnings Call Transcripts
Nektar Therapeutics (NKTR) Q2 2026 Earnings Call: REZPEG Phase III Advances
Nektar Therapeutics Q2 2026 earnings call: $1.02 billion in cash, raised year-end cash guidance, and new timelines for REZPEG Phase III programs.
Financial Indicators
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
Earnings
Next reporting date
--
Reporting Period
2026Q2
Earnings / Forecast
-1.23/-1.98
Revenue / Forecast
10.13M/10.42M
Nektar Therapeutics Profile
SectorBiotechnology & Medical Research
Ticker SymbolNKTR
Number of employees61
CountryUnited States of America
Ownership
| Shareholders | Proportion |
|---|---|
| Two Seas Capital LP | 5.80% |
| BVF Partners L.P. | 4.62% |
| Vanguard Capital Management, LLC | 3.54% |
| Two Sigma Investments, LP | 2.31% |
| Shareholder Types | Proportion |
|---|---|
| Hedge Fund | 27.41% |
| Investment Advisor | 16.52% |
| Investment Advisor/Hedge Fund | 8.34% |
| Research Firm | 4.05% |
Related Instruments
-0.65%
-0.29%
+0.33%
+0.83%
-0.54%
-0.23%
-1.34%
-0.75%
+0.25%
-2.14%
+0.17%
-0.17%
+0.12%
+0.07%
+0.02%
-1.48%
+0.04%
+0.83%
+5.38%
-0.61%Popular Instruments
52422.900
-130.100 (-0.25%)
29062.700
-306.200 (-1.04%)
7618.900
-37.700 (-0.49%)
14433.000
-23.000 (-0.16%)
63518.000
-1161.000 (-1.79%)
6280.500
-39.300 (-0.62%)
100.533
+2.176 (+2.21%)
332.270
+5.700 (+1.75%)
218.290
-0.070 (-0.03%)
4337.780
-10.270 (-0.24%)
FAQs
What is the current price of Nektar Therapeutics (NKTR)?
The current price of Nektar Therapeutics (NKTR) is 69.76.
What is the symbol of Nektar Therapeutics?
The ticker symbol of Nektar Therapeutics is NKTR.
What is the 52-week high of Nektar Therapeutics?
The 52-week high of Nektar Therapeutics is 109.00.
What is the 52-week low of Nektar Therapeutics?
The 52-week low of Nektar Therapeutics is 33.40.
What is the market capitalization of Nektar Therapeutics?
The market capitalization of Nektar Therapeutics is 2.38B.
Is Nektar Therapeutics (NKTR) currently rated as Buy, Hold, or Sell?
According to analysts, Nektar Therapeutics (NKTR) has an overall rating of Buy, with a price target of 153.22.
What is the Earnings Per Share (EPS TTM) of Nektar Therapeutics (NKTR)?
The Earnings Per Share (EPS TTM) of Nektar Therapeutics (NKTR) is -7.92.